Andrea Park Net Worth

Andrea Park biography

Andrea Park serves as Chief Financial Officer of the Company. Ms. Park had served as our Vice President of Finance and Controller since October 2019. Ms. Park’s career includes over 24 years of public accounting and finance experience. Before joining AgeX, Ms. Park served as Vice President of Finance and Controller of Lineage Cell Therapeutics, Inc., from June 2016 to September 2019, after serving as Lineage’s Controller from February 2005 to June 2016. While at Lineage, Ms. Park was directly involved in the accounting and financial reporting of the public spin-off and eventually the deconsolidation of three of its then subsidiaries including Asterias Biotherapeutics, Inc., OncoCyte Corporation and AgeX. She has also worked in the audit and assurance practice at Deloitte. Ms. Park has a B.A. in Business Economics with Concentration in Accounting from the University of California, Santa Barbara.

What's Andrea Park's mailing address?

Andrea's mailing address filed with the SEC is C/O AGEX THERAPEUTICS, INC., 1101 MARINA VILLAGE PARKWAY, SUITE 201, ALAMEDA, CA, 94501.

Insiders trading at AgeX Therapeutics Inc

Over the last 6 years, insiders at AgeX Therapeutics Inc have traded over $0 worth of AgeX Therapeutics Inc stock and bought 23,000 units worth $15,440 . The most active insiders traders include Gregory Bailey, Michael D West a Judith Segall. On average, AgeX Therapeutics Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,024. The most recent stock trade was executed by Michael D West on 11 March 2023, trading 3,125 units of AGE stock currently worth $34,688.

What does AgeX Therapeutics Inc do?

agex therapeutics, inc., a biotechnology company, focuses on the development and commercialization of novel therapeutics targeting human aging and degenerative diseases in the united states. the company's lead cell-based therapeutic candidates in development include agex-bat1, a cell therapy product candidate for the treatment of various age-related metabolic disorders, such as type ii adult-onset diabetes; and agex-vasc1, a cell-based therapy to restore vascular support in aged ischemic tissues, such as the ischemic heart. its lead drug-based therapeutic candidate in discovery is agex-itr1547, a drug-based formulation to restore regenerative potential in a range of aged tissues afflicted with degenerative diseases. in addition, the company markets human embryonic stem cells; and genecards database suite, including genomic interpretation algorithms and analysis tools for use by researchers at pharmaceutical and biotechnology companies, and other institutions. agex therapeutics, inc. ha

AgeX Therapeutics Inc executives and stock owners

AgeX Therapeutics Inc executives and other stock owners filed with the SEC include:

• Michael West,
  Chief Executive Officer, Founder, Director
• Dr. Michael D. West Ph.D.,
  Founder, Pres, CEO & Director
• Dr. Michael D. West,
  Founder, Pres, CEO & Director
• Nafees Malik,
  Chief Operating Officer
• Gregory Bailey,
  Independent Chairman of the Board
• Hal Sternberg,
  Vice President - Research
• Dr. Nafees Naseer Malik M.D.,
  Chief Operating Officer
• Eun-Jae Park CPA,
  Chief Financial Officer
• Michael May,
  Independent Director
• Annalisa Jenkins,
  Independent Director
• Andrea Park,
  Chief Financial Officer
• Judith Segall,
  Sec.
• Dr. Ivan Labat,
  Chief Information Officer
• Andrea Eun-Jae Park CPA,
  Chief Financial Officer
• Judith Segall,
  Director of Admin & Secretary
• Ltd Juvenescence,
  Director
• John F Mauldin,
  Director
• Michael H. Mulroy,
  Director
• Joanne M. Hackett,
  Director